Replies to post #43602 on Biotech Values

[iwfal]

I do point out that there were some improvements in plaque reduction in the secondary endpoints in ILLUMINATE

I would suggest that this should worry a CETP inhibitor fan - that it causes more deaths while having some positive effect on atheroma volume. It means that inhibition of CETP is making the remaining atheroma more rupture prone.

[AlpineBV_Miller]

I'd call the secondary endpoints coincidental to the fact that a huge boost in HDL got essentially nothing in interarterial plague volume reduction and a negative effect on arterial thickness.

It's a class effect.